• Ixekizumab is a new anti-interleukin-17A monoclonal antibody that is currently vying for US Food and Drug Administration approval for the treatment of psoriasis.

• In Phase III studies of ixekizumab in the treatment of plaque psoriasis, ixekizumab was shown to have Psoriasis Area and Severity Index 75 values as high as 90% at 12 weeks and continued efficacy through 60 weeks.

• Ixekizumab’s safety profile seems favorable, with the most frequently reported adverse events consisting of nasopharyngitis, upper respiratory tract infection, injection-site reaction, and headache.